Tyra Biosciences, Inc. (TYRA)

Nasdaq: TYRA · Pharmaceutical Preparations · Carlsbad, CA · filing with the SEC since 2021

Full chart Alerts Compare

Grade5.6

◀ Past 6.1● Present 5.9▶ Future 5.0

6 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

Who owns Tyra Biosciences, Inc.

As filed with the SEC

Holders of 5% or more

RA Capital Management, L.P. holds 19.9% of Common Stock, $0.0001 par value per share, as its SCHEDULE 13D/A filed Sep 17, 2026 says.

Directors and officers

report now, of 31 people on the record since 2021. Their holdings as a group are not read here.

Institutions as a whole

n/a

The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 8 named at left.

Holders of 5% or moreshare of the class, as filed

RA Capital Management, L.P.

SCHEDULE 13D/A · filed Sep 17, 2026 · Common Stock, $0.0001 par value per share · 21.2% in Mar 6, 2026

19.9%

Fmr LLC

SCHEDULE 13G · filed Apr 7, 2026 · COMMON STOCK · 3.2% in May 12, 2025

14.4%

Janus Henderson Group PLC

SCHEDULE 13G/A · filed May 15, 2026 · Common Stock · 5.4% in Aug 14, 2025

7.2%

Dapice Joshua J.

SCHEDULE 13G/A · filed May 12, 2026 · Common Stock, $0.0001 par value per share (the "Shares") · 5.6% in Feb 20, 2026

6.6%

Bvf Partners L P/il

SCHEDULE 13G · filed Sep 21, 2026 · Common Stock, $0.0001 par value per share · 4% in Feb 17, 2026

6.1%

Nextech VI Oncology SCSp

SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.0001 par value

Paradigm BioCapital Advisors LP

SCHEDULE 13G · filed Sep 17, 2026 · Common Stock, $0.0001 par value per share

5.8%

TCG Crossover GP I, LLC

SCHEDULE 13G · filed Mar 6, 2025 · Common Stock, par value $0.0001 per share

5.7%

Blackrock, Inc.

SCHEDULE 13G/A · filed Oct 27, 2026 · Common Stock · reported falling below 5%, from 5% in Jul 30, 2026

under 5%

Todd Harris

SCHEDULE 13G/A · filed May 14, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.1% in Feb 13, 2026

under 5%

Vestal Point Capital, LP

SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.4% in May 15, 2025

under 5%

Commodore Capital LP

SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 6.3% in Nov 14, 2025

under 5%

Canaan XI L.P.

SCHEDULE 13G/A · filed Apr 24, 2026 · COMMON STOCK, $0.0001 PAR VALUE PER SHARE · reported falling below 5%, from 5.5% in Feb 13, 2026

under 5%

Farallon Capital Management, L.L.C.

SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.0001 par value per share (the "Shares") · reported falling below 5%

under 5%

What TYRA reports owning in othersstakes of 5% or more, and other ties

Tyra Biosciences, Inc. reports no stake in another company in the record.

Insider tradesForm 4

14sales

1purchases

13sales on a scheduled plan

3people selling

$10.6Msold, in dollars

$0bought, in dollars

Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.

By calendar yearSoldBought

2123242526

2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.

People who traded in the window4 of 48 on the roster

Person	Role as filed	Sales	Sold	On a plan	Buys	Bought
More Robert J	director	2	$5.2M	2	0	$0
Bensen Daniel	Chief Discovery Officer	11	$4.8M	11	0	$0
Kaplan Gilla	director	1	$500,000	0	0	$0
Verjee Rehan	director	0	$0	0	1	$0

SI Assistanton TYRA · research, not advice